Published in Biochemistry on April 06, 2010
4-aminophenylalanine as a biocompatible nucleophilic catalyst for hydrazone ligations at low temperature and neutral pH. Bioconjug Chem (2011) 0.94
Microtubule drugs: action, selectivity, and resistance across the kingdoms of life. Protoplasma (2014) 0.90
Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding. Cell Cycle (2011) 0.90
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature (2004) 6.77
Preparation of tubulin from brain. Methods Enzymol (1982) 3.39
Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol (1998) 3.03
Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol (1998) 2.78
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev (1998) 2.12
Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents (2005) 2.10
Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell (1987) 2.02
The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype. J Cell Biol (1986) 1.97
Colcemid inhibition of cell growth and the characterization of a colcemid-binding activity in Saccharomyces cerevisiae. J Cell Biol (1972) 1.89
Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton (2003) 1.76
Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem (1990) 1.71
Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res (2006) 1.67
Reversible dissociation of the alpha beta dimer of tubulin from bovine brain. Biochemistry (1978) 1.65
A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol (2001) 1.54
Interactions of colchicine with tubulin. Pharmacol Ther (1991) 1.43
Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim Biophys Acta (1978) 1.36
Isolation of microtubule protein from chicken erythrocytes and determination of the critical concentration for tubulin polymerization in vitro and in vivo. J Biol Chem (1983) 1.31
Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J Biol Chem (1992) 1.31
Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry (1992) 1.30
Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther (2009) 1.26
Kinetics and mechanism of colchicine binding to tubulin: evidence for ligand-induced conformational change. Biochemistry (1978) 1.25
The biochemical basis of anthelmintic action and resistance. Int J Parasitol (2001) 1.17
In vivo coassembly of a divergent beta-tubulin subunit (c beta 6) into microtubules of different function. J Cell Biol (1987) 1.11
Tubulin proteomics: towards breaking the code. Anal Biochem (2008) 1.10
Erythrocyte microtubule assembly in vitro. Determination of the effects of erythrocyte tau, tubulin isoforms, and tubulin oligomers on erythrocyte tubulin assembly, and comparison with brain microtubule assembly. J Biol Chem (1985) 1.09
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol (2006) 1.09
Podophyllotoxin as a probe for the colchicine binding site of tubulin. J Biol Chem (1977) 1.02
The sequence and expression of the divergent beta-tubulin in chicken erythrocytes. J Biol Chem (1987) 1.00
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf (2006) 0.99
Comparative modelling of human β tubulin isotypes and implications for drug binding. Nanotechnology (2006) 0.99
The biochemistry of compounds with anti-microtubule activity in plant cells. Pharmacol Ther (1991) 0.98
The roles of cys124 and ser239 in the functional properties of human betaIII tubulin. Cell Motil Cytoskeleton (2008) 0.96
Dynamics of microtubules from erythrocyte marginal bands. Mol Biol Cell (1993) 0.93
The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle (2009) 0.90
Spectroscopic and kinetic features of allocolchicine binding to tubulin. Biochemistry (1989) 0.88
Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem (1991) 0.86
Interaction of desacetamidocolchicine, a fast binding analogue of colchicine with isotypically pure tubulin dimers alpha beta II, alpha beta III, and alpha beta IV. J Biol Chem (1994) 0.85
Role of the colchicine ring A and its methoxy groups in the binding to tubulin and microtubule inhibition. Biochemistry (1998) 0.85
Erythrocyte microtubule assembly in vitro. Tubulin oligomers limit the rate of microtubule self-assembly. J Biol Chem (1986) 0.85
Roles of colchicine rings B and C in the binding process to tubulin. Biochemistry (1989) 0.84
Synthesis and tubulin binding of novel C-10 analogues of colchicine. J Med Chem (1993) 0.83
Promotion of tubulin assembly by poorly soluble taxol analogs. Anal Biochem (2006) 0.83
Crystallization of a macromolecular ring assembly of tubulin liganded with the anti-mitotic drug podophyllotoxin. J Struct Biol (1999) 0.83
Preparation of nucleotide-depleted F1 and binding of adenine nucleotides and analogs to the depleted enzyme. Methods Enzymol (1979) 0.83
Association of thiocolchicine with tubulin. Biochem Biophys Res Commun (1989) 0.83
Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin. Bioorg Med Chem Lett (2009) 0.81
Immobilization-dependent fluorescence of colchicine. J Biol Chem (1984) 0.81
Differential interaction of tubulin isotypes with the antimitotic compound IKP-104. Biochemistry (2000) 0.81
Effect of the B ring and the C-7 substituent on the kinetics of colchicinoid-tubulin associations. Biochemistry (1993) 0.80
Alterations of rings B and C of colchicine are cumulative in overall binding to tubulin but modify each kinetic step. Biochemistry (1996) 0.79
Rapid purification of tubulin from tissue and tissue culture cells using solid-phase ion exchange. Anal Biochem (1995) 0.78
The mechanism of tubulin-colchicine recognition--a kinetic study of the binding of a bicyclic colchicine analogue with a minor modification of the A ring. Eur J Biochem (1997) 0.78
The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach. J Mol Biol (2000) 0.78
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem (2007) 1.42
The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs. Proc Natl Acad Sci U S A (2004) 1.37
Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation. J Am Chem Soc (2007) 1.34
The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle (2005) 1.16
Site-specific orthogonal labeling of the carboxy terminus of alpha-tubulin. ACS Chem Biol (2010) 0.93
A fluorescence-based high-throughput assay for antimicrotubule drugs. Anal Biochem (2003) 0.92
Bridging converts a noncytotoxic nor-paclitaxel derivative to a cytotoxic analogue by constraining it to the T-Taxol conformation. Org Lett (2006) 0.91
Recognition of an unnatural difluorophenyl nucleotide by uracil DNA glycosylase. Biochemistry (2004) 0.88
Design, synthesis, and bioactivity of simplified paclitaxel analogs based on the T-Taxol bioactive conformation. Bioorg Med Chem (2006) 0.88
Synthesis and biological evaluation of B-ring modified colchicine and isocolchicine analogs. Bioorg Med Chem Lett (2006) 0.84
Dissecting paclitaxel-microtubule association: quantitative assessment of the 2'-OH group. Biochemistry (2013) 0.83
Promotion of tubulin assembly by poorly soluble taxol analogs. Anal Biochem (2006) 0.83
Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer. J Nat Prod (2004) 0.83
Plant cell-wall cross-links by REDOR NMR spectroscopy. J Am Chem Soc (2010) 0.82
Design, synthesis and biological evaluation of bridged epothilone D analogues. Org Biomol Chem (2008) 0.81
Interaction of tubulin with a new fluorescent analogue of vinblastine. Biochemistry (2002) 0.81
Synthesis, cytotoxic properties and tubulin polymerization inhibitory activity of novel 2-pyrazoline derivatives. Arch Pharm (Weinheim) (2012) 0.80
Rotational-echo double-resonance NMR-restrained model of the ternary complex of 5-enolpyruvylshikimate-3-phosphate synthase. J Biomol NMR (2004) 0.80
Characterization of the complex of a trifluoromethyl-substituted shikimate-based bisubstrate inhibitor and 5-enolpyruvylshikimate-3-phosphate synthase by REDOR NMR. Biochemistry (2004) 0.79
Enhanced microtubule binding and tubulin assembly properties of conformationally constrained paclitaxel derivatives. Biochemistry (2007) 0.79
Novel epothilone lactones by an unusual diversion of the Grubbs' metathesis reaction. Chem Commun (Camb) (2010) 0.78
C6-C8 bridged epothilones: consequences of installing a conformational lock at the edge of the macrocycle. Chemistry (2011) 0.78
High-throughput screening of microtubule-interacting drugs. Methods Mol Med (2007) 0.78
Survivin is not induced by novel taxanes. Mol Pharm (2010) 0.78
(15)N{(31)P} REDOR NMR studies of the binding of phosphonate reaction intermediate analogues to Saccharomyces cerevisiae lumazine synthase. Biochemistry (2008) 0.78
Syntheses and bioactivities of macrocyclic paclitaxel bis-lactones. Bioorg Med Chem (2004) 0.78
Design and synthesis of simplified taxol analogs based on the T-Taxol bioactive conformation. Bioorg Med Chem (2011) 0.77
Design and synthesis of a combinatorial chemistry library of 7-acyl, 10-acyl, and 7,10-diacyl analogues of paclitaxel (taxol) using solid phase synthesis. J Nat Prod (2002) 0.76
Human factor Xa bound amidine inhibitor conformation by double rotational-echo double resonance nuclear magnetic resonance and molecular dynamics simulations. J Med Chem (2003) 0.76
Synthesis of isotopically labeled epothilones. J Labelled Comp Radiopharm (2013) 0.75
Synthesis and bioactivity of a side chain bridged paclitaxel: A test of the T-Taxol conformation. Bioorg Med Chem Lett (2009) 0.75
Design, synthesis and biological evaluation of a simplified fluorescently labeled discodermolide as a molecular probe to study the binding of discodermolide to tubulin. Bioorg Med Chem (2011) 0.75
Formation of hydrazones and stabilized boron-nitrogen heterocycles in aqueous solution from carbohydrazides and ortho-formylphenylboronic acids. Org Biomol Chem (2017) 0.75
Synthesis and biological activity of 2,5-diaryl-3-methylpyrimido[4,5-c]quinolin-1(2H)-one derivatives. Bioorg Med Chem (2007) 0.75
Synthesis and biological evaluation of C-3'NH/C-10 and C-2/C-10 modified paclitaxel analogues. Bioorg Med Chem (2003) 0.75
Synthesis and biological evaluation of N-(arylsulfanyl)carbonyl analogues of paclitaxel (taxol). Chem Biodivers (2006) 0.75
Quantification of Membrane Protein-Detergent Complex Interactions. J Phys Chem B (2017) 0.75
Synthesis, biological activity and tubulin binding poses of 1-deoxy-9-(R)-dihydrotaxane analogs. Bioorg Med Chem Lett (2008) 0.75